Ischemia of the brain due to major vessel thrombosis causes hypoxia in the respective vascular territory and subsequently induces neuronal death which is at least in part caused by apoptosis, especially in the penumbra of the lesion. 1,2 Hypoxia-inducible expression of anti-apoptotic or neurotrophic transgenes in hypoxic neurons may provide a novel therapeutic strategy for neuroprotection and alleviation of damage to ischemic brain areas.
Ischemia of the brain due to major vessel thrombosis causes hypoxia in the respective vascular territory and subsequently induces neuronal death which is at least in part caused by apoptosis, especially in the penumbra of the lesion.
1,2 Hypoxia-inducible expression of anti-apoptotic or neurotrophic transgenes in hypoxic neurons may provide a novel therapeutic strategy for neuroprotection and alleviation of damage to ischemic brain areas.
Hypoxia has been known as a potent inducer of a large number of genes including those encoding erythropoietin, vascular endothelial growth factor (VEGF), and some glycolytic enzymes, eg phosphoglycerate kinase. These genes have specific regulatory sequences in their promoter regions, known as hypoxia responsive elements (HRE). 3 Under hypoxic conditions, the upregulated hypoxia-inducible transcription factor 1 (HIF-1) binds to the HRE and initiates transcription of 3Ј sequences. This physiological mechanism has been utilized for develop- ment of hypoxia-responsive gene transfer vectors with HRE-based promoters. Hypoxia-inducible expression of transgenes has been reported in tumor cells and in cardiac myocytes. [4] [5] [6] [7] [8] [9] Recently, new hypoxia-responsive vectors for tumor-specific gene therapy were developed. 10 Constructs containing five copies of HRE derived from the 5Ј-untranslated region of the human VEGF gene showed excellent transcriptional activation at low oxygen concentrations. The combination of five HRE with a cytomegalovirus (CMV) minimal promoter exhibited excellent hypoxia responsiveness with over 500-fold induction in some cell types. Ntera2c1.D2 (NT2), a human embryonic carcinoma cell line, terminally differentiates into postmitotic neurons (NT2N) by treatment with retinoic acid, [11] [12] [13] and may be used as a cell culture model for human neurons. Nondifferentiated NT2 cells ( Figure 1A ) are rapidly dividing and may be conveniently expanded before treatment with retinoic acid, which then induces typical morphological changes with differentiation to postmitotic neurons (NT2N) ( Figure 1B ). Both NT2 cells and NT2N neurons are well transfectable with cationic liposomes (LipofectAmine; Gibco BRL, Berlin, Germany; or DOTAP, Boehringer Mannheim, Mannheim, Germany) complexed with plasmid DNA, also known as lipoplexes. The expression cassettes in the plasmid vectors used in this study were constructed with CMV promoters or HRE promoters as shown in Figure 2 .
units (RLU)/mg protein). Control NT2 cells transfected with pHRE-luciferase had a rather low activity (4.9 × 10 6 RLU/mg protein), which was induced 34-fold under hypoxic conditions. Four-fold induction of luciferase expression was obtained in hypoxic NT2N neurons transfected with pHRE compared with normoxic controls. The hypoxia-induced luciferase expression in NT2N cells was 34% of the activity of pCMV-luciferase under the same conditions. Transfection of NT2N neurons with pCMV-bcl2 or pHRE-bcl2 was demonstrated to reduce significantly the numbers of apoptotic cells after hypoxia. These results demonstrate efficient VEGF promoter-mediated induction of transgene expression in
NT2 cells transfected with the pCMV-luciferase (pCMV-luc) vector had a 400% higher luciferase (luc) activity (2.4 × 10 8 relative light units, RLU/mg protein) compared with the luc activity of pCMV-luc transfected NT2N neurons (0.6 × 10 8 RLU/mg protein) (Figure 3a ). This finding is in line with the fact that postmitotic cells have a lower expression rate after lipoplex transfection than highly mitotic (tumor) cells. 14 The cationic liposomal preparations LipofectAmine and DOTAP were further tested for efficiency of cell transduction in the presence or absence of fetal calf serum (FCS) in the culture medium. NT2 cells and NT2N neurons were efficiently transfected with the pCMV-luc vector in medium without FCS (Optimem; Gibco BRL), while addition of 10% FCS (Sigma, Deisenhofen, Germany) drastically reduced the efficiency of transduction in both cell types. DOTAP liposomes were significantly more efficient than LipofectAmine in the presence of FCS, especially in NT2N neurons. Luc activity in NT2N neurons transfected with DOTAP in 10% FCS-containing medium (DMEM; Gibco BRL) reached 12.9% of the maximum luc activity in NT2N in medium without FCS (100%). The luc activity of DOTAP transfected NT2 cells in FCS-containing medium was 6.6% of control ( Figure 3b ). Luc activity of LipofectAmine-transfected cells in FCS-containing medium was significantly lower: 0.5% of control (100%) activity in NT2 cells transfected in serum-free medium, and 1.5% of control in NT2N neurons. Human serum albumin (HSA) has been reported to enhance transfection of cultured cells in presence of FCS. 15 In our series of experiments, transfection with DOTAP/HSA/pCMV-luc complexes in the presence of FCS was able to increase marker gene expression by 200% in both NT2 cells and NT2N neurons, compared with the same experiment without the addition of HSA (Figure 3c ). NT2 cells transfected with the pHRE-luc vector under normoxic conditions showed a rather low luc activity (4.9 × 10 6 RLU/mg protein). After 6 h of hypoxia, luc expression increased 34-fold and reached 69% of the maximum luc activity in NT2 cell transfected with pCMV-luc under hypoxic conditions (Figure 3d ). NT2N neurons transfected with pHRE-luc showed low luc activity under normoxic conditions (0.8 × 10
6 RLU/mg protein), while hypoxia increased luc activity by 400% and reached expression levels of 36% of the maximum activity of pCMV-luc in NT2N under the same conditions (Figure 3e ). In NT2 cells and NT2N neurons transfected with pCMV-luc, unlike with pHRE-luc, hypoxia showed little influence on luc expression. This suggests specific hypoxia-induced transcription of genes under the control of the VEGF-derived HRE/CMV promoter.
Hypoxia-induced transgenic expression of the human bcl2 protein in NT2 cells and NT2N neurons mediated by the pHRE-bcl2 vector was able to reduce significantly apoptosis compared with the mock-transfected control groups. NT2N cells transfected with pCMV-bcl2 had a lower apoptosis rate compared with NT2N pHRE-bcl2 (Figure 3f and g ). High level ubiquitous intracellular expression of the human bcl2 protein in NT2 cells and NT2N neurons was confirmed immunocytochemically by fluorescent staining with a mouse anti-human bcl2-antibody (Dianova, Hamburg, Germany) ( Figure 4A and B) .
Our results demonstrate that in vitro differentiated human neurons, NT2N, used as a cell culture model for neuronal cells in the CNS, may be efficiently transduced with non-virus gene transfer vectors, liposome-plasmid DNA complexes, to express transgenic marker proteins and anti-apoptotic proteins in a hypoxia-specific manner. This model and the described therapeutic vector may be used in further cell culture and in vivo studies of gene transfer and therapy for acute ischemic damage of neuronal cells.
Hypoxia is a strong stimulus for upregulation of a large number of genes in eukaryotic cells. 16, 17 Specific hypoxia-responsive elements (HRE) have been cloned and employed for expression of therapeutic transgenes in hypoxic tumor cells. 4, 9, 18 Using HRE from the mouse phosphoglycerate kinase 1 gene (pgk1) to drive expression of cytosine deaminase (CD), Dachs et al 4 demonstrated that CD was induced 6.8-fold under hypoxic conditions and caused tumor cell killing when the prodrug 5-fluocytosine (5-FC) was administered. Koshikawa et al 9 showed in lung carcinoma cells hypoxia-inducible expression of herpes simplex virus type 1 thymidine kinase (HSVtk) under the control of HRE elements from the human VEGF promoter. In vivo experiments with systemic GCV administration resulted in significant tumor regression. Ruan et al 18 demonstrated that HRE-regulated bax provides a promising tool for targeted killing of hypoxic brain tumor cells. Hypoxia-inducible transgene expression was also achieved in culture and in vivo in ischemic myocardial cells using HRE from the human erythropoietin promoter. 5 In the present study, we used a recently described hypoxia-responsive plasmid vector based on five copies of the HRE from the human VEGF promoter. 10 In both NT2 cells and NT2N neurons, this vector showed a low background expression under normoxic conditions. In comparison, hypoxia for 6 h was able to induce luc expression 34-fold in NT2 cells and four-fold in NT2N neurons. Hypoxia-induced expression of the anti-apoptotic protein bcl2 in hypoxic NT2 cells and NT2N neurons significantly inhibited apoptosis. The amount of bcl2 induction seemed to correlate with the degree of apoptosis protection, since NT2 cells were better protected than NT2N neurons (32% versus 22% reduction of apoptosis). In comparison, NT2 cells and NT2N neurons transfected with the non-inducible vector pCMV-bcl2 had essentially the same degree of apoptosis protection (40% versus 42% reduction of apoptosis) (Figure 3g ). Bcl-2 expression before hypoxia apparently results in better protection compared with expression after hypoxia, since pCMV-bcl2 transfected NT2 cells and NT2N neurons have a lower apoptosis rate than their pHRE-bcl2 transfected counterparts. These differences are, however, not statistically significant, and may be due in part to different levels of bcl2 expression in pCMV-or pHRE-transfected cells.
It has been previously shown that the bcl2 protein has neuroprotective functions and may inhibit in culture and in vivo ischemic cell death. 19, 20 These studies, however, used genetically engineered virus vectors such as adenoassociated virus (AAV) 19 or herpes-simplex type I virus Gene Therapy (HSV). 20 Besides the potentially higher biological risk through the transfer of virus genes not necessary for the treatment, with these vectors there is a realistic possibility of permanent integration and expression of transgenic bcl2 in neuronal, glial and endothelial cells in the CNS. Since bcl2 is overexpressed in many human tumors 21 and in tumor vasculature, 22 the integrating virus vector approach may be even associated with a long-term oncogenic potential of the treatment. On the other hand, as lipoplexes do not integrate in the genome of the target cells, and transgenic expression from plasmid vectors is turned off after a relatively short period of time, 23 lipoplex-mediated bcl2 gene transfer immediately after acute ischemic infarction in the brain would allow for elimination of the transgene after the anti-apoptotic protection has taken place in the early phase of the infarction.
It has been already known that gene transfer efficiency in primary cell cultures is much lower than in the most immortalized cell lines. Mortimer et al 14 showed that mitotic cells have increased transfectability compared with the low transfection rates in postmitotic cells. In agreement with these findings, our studies showed that the transgene expression in postmitotic NT2N neurons was four-fold lower than in undifferentiated NT2 cells. So far, for studies of transgene expression in vitro, most investigators used undifferentiated cell lines in an exponential growth phase, which may explain why the systems that had good activity in vitro were subsequently found to be less efficient in vivo. 24, 25 Since we were able to demonstrate transgene expression rates sufficient for survival of postmitotic NT2N neurons, further studies with terminally differentiated cell cultures should provide a better model for prediction of in vivo gene transfer efficacy and neural protection by anti-apoptotic and neurotrophic proteins.
In addition, we analyzed the influence of serum on liposome-mediated gene transfer in NT2 and NT2N cells. FCS proteins have been reported to inhibit liposomemediated gene transfer, although it is still not clear exactly how they may impede liposomal DNA transfer to cells. [26] [27] [28] [29] Recently, Pires et al 30 showed that the fusion of cationic liposome/DNA complexes with cell membranes was completely abolished in the presence of 3% FCS. These authors suggested that the large amounts of negatively charged proteins in serum constitute a physical and electrostatic barrier that prevents membrane fusion and binding of the lipoplexes. In our present study, addition of 10% FCS drastically reduced the efficiency of liposomal gene transfer and subsequent marker gene expression with both preparations, although DOTAP liposomes performed significantly better than LipofectAmine, especially in NT2N neurons. Addition of 20% HSA to the liposome/DNA complexes was able to partially compensate for loss of transduction efficiency due to FCS presence in both NT2 cells and NT2N neurons. As reported previously, 15 coating cationic liposomes with HSA may increase liposomal transduction rates in vivo or in culture under serum conditions. This may be explained by the fact that HSA-lipoplexes are negatively charged, unlike the highly positively charged cationic liposome/DNA complexes, 15 which may be sufficient to overcome some of the difficulties associated with the use of these vectors for gene delivery to hypoxic neurons in vivo.
In conclusion, the presented model for hypoxia- Figure 3 ( inducible non-virus vector gene transfer seems to offer anti-apoptotic protection of human postmitotic neurons in culture. However, the reported findings have to be validated in animal models of acute cerebral ischemia before further discussion of a possible clinical application of this strategy. 
